-

Harrow to Present at Three Investor Conferences in September in New York

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences in September in New York:

H.C. Wainwright 26th Annual Global Investment Conference (Lotte New York Palace Hotel)
September 9-11, 2024
Company will present at 8:00 a.m. ET on September 10, 2024

Lake Street 8th Annual Best Ideas Growth Conference – Big 8 (The Yale Club)
September 12, 2024
1x1 Meetings Only

Cantor 2024 Global Healthcare Conference (InterContinental New York Barclay Hotel)
September 17-19, 2024
Company will host a Fireside Chat at 2:30 p.m. ET on September 18, 2024

The Company will conduct one-on-one meetings at each conference. Investors interested in meeting with management during conferences should contact their representative at each firm to request a meeting. To listen to the audio webcast of either the H.C. Wainwright or Cantor conferences, please visit the Company’s website. The Lake Street conference will not be webcast.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.

Contacts

Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737

Industry:

Harrow, Inc.

NASDAQ:HROW
Release Versions
English
$Cashtags
$HROW

Contacts

Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737

More News From Harrow, Inc.

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

NASHVILLE--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter “Samsung Bioepis”) to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar refer...

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. “We are excited to welcome Mike to the Harrow Family. His wealth of exper...

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

NASHVILLE, Tenn. & TAIPEI, Taiwan--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain...
Back to Newsroom